OrganOx Ltd., a leading organ medical technology company, completed a second closing of its private placement with investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC. Together with the first closing of its private placement on February 24, 2025, OrganOx raised $160 million in primary and secondary equity financing to accelerate growth opportunities for its metra® platform technology in the large and high growth organ technology global market.
Related: InBrain awarded €4m to accelerate development of its BCI platform
Approved in the U.S., Europe, Canada, and Australia, the OrganOx metra® is a normothermic machine perfusion (NMP) platform technology utilized in over 5,000 liver transplants to date. The metra® keeps donor livers in a metabolically active state outside the body, providing transplant teams with the opportunity for functional assessment of the organ prior to transplant which leads to an increased number of organs available for transplant, while also extending liver preservation times as compared to static cold storage. The company is also expanding its metra® technology for kidney transplants, currently in development, and in collaboration with eGenesis, recently gained FDA clearance to begin a first-in-human clinical study of the use of its metra® technology combined with eGenesis’ genetically engineered porcine livers to support patients with acute-on-chronic liver failure.
“It is an honor and a privilege to have Intuitive Ventures and Terumo Ventures invest in OrganOx,” said Oern R. Stuge, MD, MBA, Executive Chairman at OrganOx. “Our board and management team look forward to working together with these industry leaders to further advance our organ technologies that save patient lives.”
Piper Sandler acted as exclusive financial advisor and Latham & Watkins acted as legal counsel to OrganOx in this transaction.
